Dr. Reddy's Laboratories Limited has informed the Exchange regarding 'Revised Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information.'
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's Laboratories has submitted a revised 'Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information' to the stock exchanges. The revised code was approved by the Board of Directors on March 24, 2026, and is filed under SEBI's Insider Trading Regulations, 2015. The code outlines how the company will handle, share, and disclose price-sensitive information uniformly to avoid selective disclosure, including rules for analyst interactions, legitimate purpose sharing, and a structured digital database of who receives UPSI. The company must publicly disseminate any inadvertently leaked UPSI within 24 hours and restrict sharing of such information to those with a legitimate need-to-know. This is a routine, mandatory compliance update and the full code is available on the company's website.
This is a standard regulatory compliance filing with no material impact on shareholders or the stock price. It reinforces the company's existing framework to prevent insider trading and ensure fair disclosure, which is positive for corporate governance.